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Abstract
Infectious and inflammatory diseases have repeatedly shown strong genetic associations within the
major histocompatibility complex (MHC); however, the basis for these associations remains
elusive. To define host genetic effects on the outcome of a chronic viral infection, we performed
genome-wide association analysis in a multiethnic cohort of HIV-1 controllers and progressors,
and we analyzed the effects of individual amino acids within the classical human leukocyte
antigen (HLA) proteins. We identified >300 genome-wide significant single-nucleotide
polymorphisms (SNPs) within the MHC and none elsewhere. Specific amino acids in the HLA-B
peptide binding groove, as well as an independent HLA-C effect, explain the SNP associations and
reconcile both protective and risk HLA alleles. These results implicate the nature of the HLA–viral
peptide interaction as the major factor modulating durable control of HIV infection.
Hiv infection is characterized by acute viremia, often in excess of 5 million viral particles
per milliliter of plasma, followed by an average 100-fold or greater decline to a relatively
stable plasma virus load set point (1). In the absence of antiretroviral therapy, the level of
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viremia is associated with the rate of CD4+ T cell decline and progression to AIDS. There is
substantial interperson variability in the virus load set point, with most individuals having
stable levels exceeding 10,000 RNA copies/ml. Yet a small number of people demonstrate
sustained ability to control HIV replication without therapy. Such individuals, referred to as
HIV controllers, typically maintain stable CD4+ cell counts, do not develop clinical disease,
and are less likely to transmit HIV to others (2).
To determine the genetic basis for this rare phenomenon, we established a multinational
consortium (www.hivcontrollers.org) to recruit HIV-1 controllers, who are defined by at
least three measurements of plasma virus load (VL) < 2000 RNA copies/ml over at least a
12-month period in the absence of antiviral therapy. We performed a genome-wide
association study (GWAS) in the HIV controllers (median VL, CD4 count, and disease
duration of 241 copies/ml, 699 cells/mm3, and 10 years, respectively) and treatment-naïve
chronically infected individuals with advanced disease (median VL and CD4 count of
61,698 copies/ml and 224 cells/mm3, respectively) enrolled in antiviral treatment studies led
by the AIDS Clinical Trials Group. After quality control and imputation on the basis of
HapMap Phase 3 (3), we obtained data on 1,384,048 single-nucleotide polymorphisms
(SNPs) in 974 controllers (cases) and 2648 progressors (controls) from multiple populations
(table S1).
After stratification into European, African American, and Hispanic ethnic groups (fig. S1),
we tested each SNP for association using logistic regression, including the major principal
components as covariates to correct for population substructure (4). In the largest group,
comprising 1712 individuals of European ancestry, we identified 313 SNPs with genome-
wide significance, defined by P < 5 × 10−8 due to correction for multiple comparisons (table
S2). All SNPs that reached genome-wide significance were located in the major
histocompatibility complex (MHC) region on chromosome 6 (Fig. 1A). We obtained similar
results for the other two ethnic groups and in a meta-analysis of all participants (fig. S2). We
also performed a genome-wide analysis to test the influence of local chromosomal ancestry
in the African American sample (4), but we detected no signal outside the MHC (figs. S3
and S4). The impact of the MHC was further underscored when we specifically tested
published associations related to HIV disease progression outside the MHC. Only variants in
the CCR5-CCR2 locus—namely, CCR5Δ32 deletion polymorphism (5), C927T in CCR5
(6), and Val64→Ile64 in CCR2 (7)—replicate with nominal statistical significance in our
study (Fig. 1B and table S3).
Closer examination of the significant SNPs within the MHC showed that they are located
within a 3-Mb region concentrated around class I human leukocyte antigen (HLA) genes
(fig. S5), but extensive linkage disequilibrium (LD) makes precise assignment of causal
variants challenging (8). Therefore, we used stepwise regression to define independent
markers associated with host control. From the initial set of 313 SNPs that reached genome-
wide significance in the European sample, for which the greatest numbers of participants
were available, we found only four independent markers of association (Table 1).
rs9264942, located 35 kb upstream of HLA-C and a putative variant associated with HLA-C
expression levels [odds ratio (OR) = 2.9, P = 2.8 × 10−35, where an OR > 1 indicates a
protective effect], and rs2395029, a proxy for HLA-B*57:01 (OR = 5.3, P = 9.7 × 10−26),
had been previously reported to be associated with virus load set point after acute infection
(9). We also defined rs4418214, a noncoding SNP near MICA (OR = 4.4, P = 1.4 × 10−34),
and rs3131018 in PSORS1C3, a gene implicated in psoriasis (OR = 2.1, P = 4.2 × 10−16).
These four SNPs explain 19% of the observed variance of host control in the European
sample; together with those in CCR5, these SNPs explain 23%, using Nagelkerke’s
approximation (Fig. 1C) (10).
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In the smaller African American sample, we observed 33 SNPs with genome-wide
significance, four of which were identified as independent markers, but all differed from
those in the European sample (Table 1). This suggests that shared causal variants are tagged
by different SNPs in these two populations or that the mechanism of control differs with
ethnicity. Only rs2523608 was previously identified, in a recent study of virus load set point
in African Americans (11). Despite no evidence for historical recombination (D’ = 1), this
SNP is only weakly correlated (r2 < 0.1) with HLA-B*57:03, the class I allele most strongly
associated with durable control of HIV in populations of African ancestry (11-13). In the
Hispanic sample, which was much smaller, the most significant SNP was rs2523590, 2 kb
upstream of HLA-B, also identified in the African American sample described here.
Given the localization of significant SNPs entirely to the HLA class I region, as well as
previous studies showing HLA alleles to affect disease progression (13-20), we next sought
to evaluate whether these SNP and HLA associations might be due to specific amino acids
within HLA. Because HLA types were available for only a portion of the entire cohort, we
developed a method to impute classical HLA alleles and their corresponding amino acid
sequences (4) on the basis of haplotype patterns in an independent data set collected by the
Type 1 Diabetes Genetics Consortium (T1DGC) (21). This data set contains genotype data
for 639 SNPs in the MHC that overlap with genotyped SNPs in our GWAS and classical
HLA types for class I and II loci at four-digit resolution in 2767 unrelated individuals of
European descent.
We imputed HLA types in the European sample of our study and validated the imputations
by comparing to empirical four-digit HLA typing data collected for class I loci in a subset (n
= 371) of the HIV controllers. The quality of the imputations was such that the imputed and
true frequencies for all HLA alleles in this subset were in near-perfect agreement (Fig. 2A)
(r2 = 0.99). Furthermore, the positive predictive value was 95.2% and the sensitivity was
95.2% at two-digit resolution (92.7 and 95.6%, respectively, at four-digit resolution) for
HLA alleles with frequency >2% (Fig. 2B). This indicates that the performance of the
imputation was generally excellent for common alleles, consistent with previous work (22).
We used HLA allele imputations in all participants (even those with HLA types defined by
sequencing) for association analyses to avoid systematic bias between cases and controls.
Lower imputation quality would only decrease power, not increase the false-positive rate,
because cases and controls would be equally affected.
We tested all HLA alleles for association via logistic regression, adjusting for the same
covariates used in SNP analysis (tables S4 and S5). The most significant HLA association is
B*57:01 (OR = 5.5, P = 1.4 × 10−26), which explains the proxy association of rs2395029 in
HCP5. With the use of stepwise regression modeling in the European sample of controllers
and progressors, we were able to implicate B*57:01, B*27:05, B*14/Cw*08:02, B*52, and
A*25 as protective alleles and B*35 and Cw*07 as risk alleles. These associations are
consistent with earlier studies that highlighted a role for HLA class I loci (13-20), and
particularly HLA-B alleles in control of HIV, which indicated that the imputations are
robust. Collectively explaining 19% of the variance of host control, these HLA allele
associations are consistent with the effects of the four independent SNPs.
Virus-infected cells are recognized by CD8+ T cells after presentation of short viral peptides
within the binding groove of HLA class I, and HIV-specific CD8+ T cells are strongly
associated with control (23). We thus evaluated whether the SNP associations identified in
the GWAS, and the HLA associations derived from imputation, might be due to specific
amino acid positions within the HLA molecules, particularly those involved in the
interaction between the viral peptide and the HLA class I molecule. Using the official DNA
sequences defined for known HLA alleles (24), we encoded all variable amino acid positions
et al. Page 7
Science. Author manuscript; available in PMC 2011 December 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
within the coding regions of the HLA genes in each of the previously HLA-typed 2767
individuals in the T1DGC reference panel, and we used this data set to impute the amino
acids in the cases and controls (4). Among a total of 372 polymorphic amino acid positions
in class I and II HLA proteins, 286 are biallelic like a typical nonsynonymous coding SNP.
The remaining 86 positions accommodate more than two amino acids; position 97 is the
most diverse in HLA-B with six possible amino acids observed in European populations.
After imputing these amino acids in the European sample, we used logistic regression to test
all positions for association with host control (fig. S6 and table S6). Notably, position 97 in
HLA-B was more significant (omnibus P = 4 × 10−45) than any single SNP in the GWAS,
and three amino acid positions (67, 70, and 97), all in HLA-B, showed much stronger
associations than any single classical HLA allele, including B*57:01 (Fig. 3A). Moreover,
allelic variants at these positions were associated with substantial frequency differences
between cases and controls (Fig. 3B). These results indicate that the effect of HLA-B on
disease outcome could be mediated, at least in part, by these positions. These three amino
acid positions are located in the peptide binding groove, which suggests that conformational
differences in peptide presentation at these sites contribute to the protective or susceptible
nature of the various HLA-B allotypes. Although both innate and adaptive mechanisms could
be at play, the hypothesis that HLA affects peptide presentation and subsequent T cell
functionality is supported by experimental data showing substantial functional differences
between CTL targeting identical epitopes but restricted by different HLA alleles (25).
We next performed stepwise regression modeling and identified six residues as independent
markers associated with durable control of HIV. These include Arg97, Cys67, Gly62, and
Glu63, all in HLA-B; Ser77 in HLA-A; and Met304 in HLA-C, which collectively explain
20% of the observed variance (similar to the variance explained by the seven classical HLA
alleles described above). With the exception of Met304 in the transmembrane domain of
HLA-C, these residues are all located in the MHC class I peptide binding groove, again
suggesting that the binding pocket—and, by inference, the conformational presentation of
class I-restricted epitopes—plays a key role in host control.
Having identified these amino acid positions as strong candidates to account for the SNP
and HLA association signals in this study, we next investigated their effects on protection or
risk, revealing allelic variants at these positions linked to both extremes (Table 2). HLA-B
position 97 (omnibus P = 4 × 10−45), located at the base of the C pocket, has important
conformational properties for peptide binding (26). Position 97 has six allelic variants:
Protective haplotypes B*57:01, B*27:05, and B*14 are uniquely defined by Val97 (3%
frequency in controls), Asn97 (4%) and Trp97 (3%), respectively; the other amino acids at
this position (Ser, Thr, Arg) segregate on a diverse set of haplotypes. Ser97 (27% frequency)
lies on risk haplotypes Cw*07, B*07, and others, where-as Thr97 (11%) lies on protective
B*52 (and others). Arg97 is the most common amino acid (51%) and is carried by risk allele
B*35, among others. The importance of this amino acid position to host control is
underscored by conditional analyses revealing significance when we adjust incrementally
for Val97 (omnibus test for position 97, P = 3 × 10−20), Asn97 (P = 2 × 10−9), and Trp97 (P
= 7 × 10−5). Thus, at a single position within the peptide binding groove (position 97, C-
pocket), discrete amino acids are associated with opposite disease outcomes, even after
controlling for B*57 and B*27, alleles associated with host control.
We also found similar discordant associations for alleles at positions 67, 63, and 62 (Table
2), all of which line the α1 helix along the peptide binding groove and help shape the B-
pocket (Fig. 4). At position 67 (omnibus P = 2 × 10−42), risk haplotypes B*35 and B*07
carry aromatic residues Phe67 and Tyr67, respectively, whereas protective B*57:01,
B*27:05, and B*14 alleles carry sulfur-containing residues Met67 or Cys67. Position 62 (P =
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5 × 10−27) is biallelic (Arg/Gly) with the Gly62 allele segregating with protective alleles
B*57:01 and B*58 (<1% frequency, OR = 1.7, P = 0.2). Adjacent position 63 (P = 9 ×
10−16) is also biallelic (Glu/Asn) with Glu63 appearing in complete LD (D’ = 1) with
B*57:01, B*27:05, and B*52. In contrast, at this position the risk alleles B*07 (14%
frequency, OR = 0.5, P = 1 × 10−7) and B*35 both carry Asn63. Position 70 (omnibus P = 3
× 10−39) accommodates four alleles that are tightly coupled with positions 67 and 97: Ser70
appears exclusively with Met67 (which defines B*57 and B*58), Gln70 with Tyr67, and
Lys70 with Asn97 (B*27). Hence, these data create a consistent and parsimonious model that
can explain the associations of classical HLA-B alleles by specific amino acids lining the
binding groove (and residues tightly coupled to them), which are expected to have an impact
on the three-dimensional structure of the peptide-MHC complex.
To further investigate the role of individual amino acid positions in HLA-B, we implemented
a permutation procedure to assess how consistent the above observations are with a null
model in which there is no relation between amino acids at a particular position and host
control (4). The results of this procedure provided evidence that multiple amino acid
positions in the peptide binding groove are indeed associated with host control (table S7),
including positions 62, 63, 67, 70, and 97, thus providing a structural basis for the effect of
HLA-B on host control (Fig. 4).
Within HLA-A position 77, which lies on the α helix contributing to the F-pocket, we
identified a weaker but still significant association (omnibus P = 3 × 10−6). Ser77 (6%
frequency, OR = 2.0, P = 2 × 10−6) is carried by only two HLA-A alleles (joint r2 = 1): A*25
(2.4% frequency, OR = 2.6, P = 1 × 10−5) and A*32 (3.2%, OR = 1.6, P = 0.02). Given its
location and earlier association evidence for the A10 supertype (27), HLA-A could play a
role in host control, although the evidence is not as strong as for HLA-B.
The signals within HLA-C are less straight-forward to interpret. Position 304 is a biallelic
variant (Val/Met) located in the transmembrane domain (Met304, 28% frequency, OR = 2.3,
P = 7 × 10−23). Met304 is in moderate LD (r2 = 0.5) with rs9264942, which is known to be
associated with HLA-C expression levels (28). Addition of this SNP to a multivariate model
of all six amino acids is marginally significant (P = 0.013) but eliminates the effect of
Met304 (P = 0.06). Similarly, addition of rs9264942 to a multivariate model of all seven
independent classical HLA alleles is also significant (P = 2 × 10−4) but eliminates the effect
of Cw*07 (P = 0.08). These observations make it difficult to determine the extent to which
epitope presentation in the HLA-C peptide binding pocket is important for host control.
Thus, rs9264942 could be a proxy for not only many protective and risk HLA alleles
(predominantly at HLA-B), but also for an independent effect on HLA-C gene expression,
differentially affecting the response to HIV (29).
We next evaluated associations for the SNPs in the MHC, classical HLA alleles, and amino
acids in a second independent cohort of untreated HIV-infected persons from Switzerland
(fig. S7 and tables S8 and S9) (4), in whom virus load set point was measured as a
quantitative trait. Allelic variants at positions 67, 70, and 97 were also associated with
highly significant differences in virus load set point in this second cohort (Fig. 3C). The
effect estimates of all variable amino acids in HLA-B (r2 > 0.9) and, to a lesser degree, those
in HLA-C (r2 > 0.8) in that cohort are in excellent agreement (figs. S8 and S9). As before,
position 97 in HLA-B is the most significant association (omnibus P = 1 × 10−13). The
HLA-A associations (A*25 or Ser77) did not replicate, which reduces the likelihood that
HLA-A plays a major role in host control.
In the African American sample (fig. S10), the most significant HLA allele association was
observed for two-digit B*57 (OR = 5.1, P = 1.7 × 10−21) and four-digit B*57:03 (OR = 5.1,
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P = 2.8 × 10−17; tables S10 and S11), consistent with previous studies (11-13). Position 97
in HLA-B (omnibus P = 2 × 10−25) is again the most significant amino acid (table S12). The
consistency of these results demonstrates that imputation and association testing at amino
acid resolution in multiple ethnicities can resolve disparate SNP associations in the MHC
and help with fine-mapping of classical HLA associations.
Altogether, these results link the major genetic impact of host control of HIV-1 to specific
amino acids involved in the presentation of viral peptides on infected cells. Moreover, they
reconcile previously reported SNP and HLA associations with host control and lack of
control to specific amino acid positions within the MHC class I peptide binding groove.
Although variation in the entire HLA protein is involved in the differential response to HIV
across HLA allotypes, the major genetic effects are condensed to the positions highlighted in
this study, indicating a structural basis for the HLA association with disease progression that
is probably mediated by the conformation of the peptide within the class I binding groove.
The most significant residue, position 97 in the floor of the peptide binding groove of HLA-
B, is associated with the extremes of viral load, depending on the expressed amino acid. This
residue has been shown to have important conformational properties that affect epitope-
contacting residues within the binding groove (26, 30) and has also been implicated in HLA
protein folding and cell-surface expression (31).
Although the main focus of this study was on common sequence variation, it remains an
open question as to the role of variants outside the MHC and the contribution of epistatic
effects and epigenetic regulation. Additional factors also contribute to immune control of
HIV, including fitness-altering mutations, immuno-regulatory networks, T cell help, thymic
selection, and innate effector mechanisms such as killer cell immunoglobulin-like receptor
recognition (23), some of which are influenced by the peptide-HLA class I complex.
However, the combination and location of the significant amino acids defined here are most
consistent with the genetic associations observed being modulated by HLA class I restricted
CD8+ T cells. These results implicate the nature of the HLA-viral peptide interaction as the
major genetic factor modulating durable control of HIV infection and provide the basis for
future studies of the impact of HLA-peptide conformation on immune cell induction and
function.
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Fig. 1.
Genome-wide association results in the European sample. (A) Manhattan plot of 1.3 million
autosomal SNPs. Only SNPs in the MHC on chromosome 6 reach genome-wide
significance, indicated by the horizontal dotted line (P < 5 × 10−8). Red and blue colors
alternate between chromosomes. (B) Quantile-quantile plot of the association results with
(black) and without (blue) SNPs in the extended MHC and the CCR5-CCR2 locus,
indicating that the detectable effect is entirely attributable to these two loci. The red line
denotes the expected distribution under the null hypothesis of no effect. (C) Distribution of
the genotype protective score, defined as the total number of alleles associated with host
control at the four independent SNPs in the MHC and the variants at CCR5-CCR2, showing
marked differences in controllers (orange) and progressors (blue). In aggregate, these
variants explain 23% of the observed variance of durable host control.
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Fig. 2.
Imputation quality of classical HLA alleles in the European sample. (A) Concordance
between imputed (y-axis) and observed (x-axis) frequencies of classical HLA types in 371
HIV-1 controllers with four-digit HLA types obtained through Sanger sequencing. (B)
Positive predictive value, sensitivity, and genotype correlation (r2) with typed alleles as a
function of the observed frequency.
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Fig. 3.
Associations at amino acids in HLA-B in the European sample. (A) Association results for
all variable amino acid positions, as calculated by the omnibus test. Colors denote
conventional pocket positions. P values for significant classical HLA-B alleles are shown for
comparison. (B) Marked allele frequency differences between controllers and progressors
for amino acids at positions 67, 70, and 97. Numbers above the bars indicate odds ratios
(values >1 indicate a protective effect). (C) Associations between allelic variants at amino
acid positions 67, 70, and 97 and quantitative virus load set point in the independent Swiss
HIV cohort study. Effect estimates (beta coefficients from a linear-regression model) are
given in log10 units of virus load set point. P values refer to the omnibus test for association
at each position. Error bars indicate the standard error of the beta coefficient.
et al. Page 14
Science. Author manuscript; available in PMC 2011 December 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Three-dimensional ribbon representation of the HLA-B protein based on Protein Data Bank
entry 2bvp (30), highlighting amino acid positions 62, 63, 67, 70, and 97 lining the peptide
binding pocket. The peptide backbone of the epitope is also displayed. This figure was
prepared with UCSF Chimera (32).
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